These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 19652957)

  • 1. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment.
    Urigüen L; García-Fuster MJ; Callado LF; Morentin B; La Harpe R; Casadó V; Lluis C; Franco R; García-Sevilla JA; Meana JJ
    Psychopharmacology (Berl); 2009 Oct; 206(2):313-24. PubMed ID: 19652957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropathology markers and pathways associated with molecular targets for antipsychotic drugs in postmortem brain tissues: exploration of drug targets through the Stanley Neuropathology Integrative Database.
    Kim S; Zavitsanou K; Gurguis G; Webster MJ
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):683-94. PubMed ID: 22356822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats.
    Di Bartolomeo M; Stark T; Maurel OM; Iannotti FA; Kuchar M; Ruda-Kucerova J; Piscitelli F; Laudani S; Pekarik V; Salomone S; Arosio B; Mechoulam R; Maccarrone M; Drago F; Wotjak CT; Di Marzo V; Vismara M; Dell'Osso B; D'Addario C; Micale V
    Pharmacol Res; 2021 Feb; 164():105357. PubMed ID: 33285233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of dopamine D
    Egusquiza I; Munarriz-Cuezva E; Segarra R; González-Maeso J; Callado LF; Meana JJ; Diez-Alarcia R
    Pharmacol Rep; 2021 Aug; 73(4):1136-1146. PubMed ID: 34196951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia.
    Eggan SM; Hashimoto T; Lewis DA
    Arch Gen Psychiatry; 2008 Jul; 65(7):772-84. PubMed ID: 18606950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A2A adenosine receptor antagonism enhances synaptic and motor effects of cocaine via CB1 cannabinoid receptor activation.
    Tozzi A; de Iure A; Marsili V; Romano R; Tantucci M; Di Filippo M; Costa C; Napolitano F; Mercuri NB; Borsini F; Giampà C; Fusco FR; Picconi B; Usiello A; Calabresi P
    PLoS One; 2012; 7(6):e38312. PubMed ID: 22715379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Adenosine-Dopamine (A2A-D2 Like) Heteroreceptor Complexes in the Brain and Their Role in Schizophrenia.
    Borroto-Escuela DO; Ferraro L; Narvaez M; Tanganelli S; Beggiato S; Liu F; Rivera A; Fuxe K
    Cells; 2020 Apr; 9(5):. PubMed ID: 32349279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex.
    Tallerico T; Novak G; Liu IS; Ulpian C; Seeman P
    Brain Res Mol Brain Res; 2001 Mar; 87(2):160-5. PubMed ID: 11245917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of clozapine and haloperidol on dopamine receptor mRNA expression in rat striatum and cortex.
    Damask SP; Bovenkerk KA; de la Pena G; Hoversten KM; Peters DB; Valentine AM; Meador-Woodruff JH
    Brain Res Mol Brain Res; 1996 Sep; 41(1-2):241-9. PubMed ID: 8883957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased [3H] raclopride binding sites in postmortem brains from schizophrenic violent suicide victims.
    Ruiz J; Gabilondo AM; Meana JJ; García-Sevilla JA
    Psychopharmacology (Berl); 1992; 109(4):410-4. PubMed ID: 1365855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors.
    Martín AB; Fernandez-Espejo E; Ferrer B; Gorriti MA; Bilbao A; Navarro M; Rodriguez de Fonseca F; Moratalla R
    Neuropsychopharmacology; 2008 Jun; 33(7):1667-79. PubMed ID: 17957223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine A
    Marques TR; Natesan S; Rabiner EA; Searle GE; Gunn R; Howes OD; Kapur S
    Psychopharmacology (Berl); 2022 Nov; 239(11):3439-3445. PubMed ID: 34175983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer.
    Navarro G; Carriba P; Gandía J; Ciruela F; Casadó V; Cortés A; Mallol J; Canela EI; Lluis C; Franco R
    ScientificWorldJournal; 2008 Oct; 8():1088-97. PubMed ID: 18956124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects.
    Muguruza C; Moreno JL; Umali A; Callado LF; Meana JJ; González-Maeso J
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):852-64. PubMed ID: 23176747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heteromer formation between cannabinoid type 1 and dopamine type 2 receptors is altered by combination cannabinoid and antipsychotic treatments.
    Bagher AM; Young AP; Laprairie RB; Toguri JT; Kelly MEM; Denovan-Wright EM
    J Neurosci Res; 2020 Dec; 98(12):2496-2509. PubMed ID: 32881145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors.
    Kull B; Ferré S; Arslan G; Svenningsson P; Fuxe K; Owman C; Fredholm BB
    Biochem Pharmacol; 1999 Sep; 58(6):1035-45. PubMed ID: 10509756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study.
    Gurevich EV; Bordelon Y; Shapiro RM; Arnold SE; Gur RE; Joyce JN
    Arch Gen Psychiatry; 1997 Mar; 54(3):225-32. PubMed ID: 9075463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D2 heteroreceptor complexes and their receptor-receptor interactions in ventral striatum: novel targets for antipsychotic drugs.
    Fuxe K; Borroto-Escuela DO; Tarakanov AO; Romero-Fernandez W; Ferraro L; Tanganelli S; Perez-Alea M; Di Palma M; Agnati LF
    Prog Brain Res; 2014; 211():113-39. PubMed ID: 24968778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia.
    Ferré S; O'Connor WT; Snaprud P; Ungerstedt U; Fuxe K
    Neuroscience; 1994 Dec; 63(3):765-73. PubMed ID: 7898676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.